Endologix LLC, has announced the online publication of the one-year results of the DETOUR2 Trial in the Journal of Vascular Surgery (JVS1). The study demonstrated that the DETOUR System offers a viable endovascular option for patients with long segment, complex superficial femoral artery (SFA) disease. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to bypass the SFA using the vein as a conduit.

The study highlighted low rates of complications, deep venous thrombosis (DVT), and clinically-driven target lesion revascularization (CD-TLR), and excellent one-year primary patency. The DETOUR2 Study enrolled 202 patients at 32 sites, and 200 patients were treated with the DETOUR system. The mean lesion length was 32.7 cm, 96% were chronic total occlusions (CTO), and 70% were severely calcified.

The results presented highlight: Freedom from CD-TLR was 87.7% through 1 year. Expressed as a binary end point, patency (defined as freedom from occlusion), was 92.4% through 12 months. Clinical success, defined as improvement in at least one Rutherford Category at 12 months, was 97.2%.

Major procedure related infection within 30 days after the index procedure was 0.5%. Freedom from major adverse events (MAEs) at 30 days was 93%. The 12-month incidence of symptomatic DVT was 4.1% with no pulmonary emboli reported.

Average length of hospital stay was 1.1 days.